陈和生是我国著名粒子物理学家，中国科学院院士、中国科学院高能物理研究所研究员，长期致力于高能实验物理研究，主持了北京正负电子对撞机重大改 造工程和中国散裂中子源两项国家重大科技基础设施建设。在东莞，有一片土地曾经是荔枝林，如今已成为孕育国家重大科技基础设施的创新高地。跟随 《回家》的脚步，总台主持人王宁记录陈和生院士，重返广东东莞的动人旅程。 八旬院士利用高能物理治疗肿瘤 院士陈和生的抗癌黑科技 王宁：硼中子治疗中心听说是肿瘤患者的希望之地。 陈和生：对，是一种新的治疗方法。患者治疗起来更方便，费用更低。硼中子俘获治疗技术能够在细胞级别上治疗肿瘤。是癌症细胞，就灭了，不是就完全 不碰。 作为中国散裂中子源工程总指挥，陈和生院士敏锐地意识到中子束在癌症治疗领域的潜力，他在2016年率先提出了"科研大装置+医疗应用"的转化思路。 当被问及，在脑部无论有多少肿瘤细胞，它都能做到百步穿杨，准确"打击"吗？陈和生院士给出了肯定的回答，并表示最多做两次就能把肿瘤细胞杀死。 高能物理与日常生活有多近 东莞松山湖畔的中国散裂中子源是最早落户粤港澳大湾区的国家重大科技基础设施，也是松山湖科学城的起点。 1984年他在美国麻省理 ...

Core Viewpoint - Japan is the only country currently possessing the BNCT (Boron Neutron Capture Therapy) technology for cancer treatment, which has shown promising results in clinical applications, particularly for head and neck tumors [1][2]. Group 1: Technology Development - The BNCT technology was first discovered in the 1930s by French researchers, with unsuccessful attempts made by Americans in the 1950s, but Japan continued its research and development [2]. - Japan began preclinical studies in 2000, started clinical trials in 2016, and received approval for the technology in March 2020, quickly integrating it into their healthcare system by June 2020 [1][2]. Group 2: Clinical Applications and Efficacy - The initial approved indications for BNCT include head and neck tumors, with ongoing research to expand its use to breast cancer, pancreatic cancer, and other types [1][4]. - Among over 800 cases treated in Japan, the three-year survival rate for certain tumors has reached 60-70%, indicating significant potential despite current limitations in applicable indications [1][4]. Group 3: Equipment and Accessibility - Currently, there are only two clinical BNCT devices in Japan, one in Fukushima and one in Osaka, with the Osaka center not yet accepting international patients due to high domestic demand [3]. - The technology's expansion and accessibility in other countries, including China, is being considered, as there is a growing interest in the treatment [3].